Results 21 to 30 of about 45,597 (259)

Pharmacology of HIV integrase inhibitors [PDF]

Current Opinion in HIV and AIDS, 2012
The purpose of this paper is to review recent and relevant pharmacology data for three HIV integrase inhibitors: raltegravir (marketed), dolutegravir and elvitegravir (both in Phase III drug development).
Jessica L, Adams, Benjamin N, Greener, Angela D M, Kashuba   +2 more
openaire   +2 more sources

Integrase residues that determine nucleotide preferences at sites of HIV-1 integration: implications for the mechanism of target DNA binding [PDF]

, 2014
Retroviruses favor target-DNA (tDNA) distortion and particular bases at sites of integration, but the mechanism underlying HIV-1 selectivity is unknown. Crystal structures revealed a network of prototype foamy virus (PFV) integrase residues that distort ...
Cherepanov, Peter, Engelman, Alan, Krishnan, Lavanya, Li, Xiang, Maertens, Goedele N., Serrao, Erik, Shun, Ming-Chieh   +6 more
core   +1 more source

Modeling the HIV-1 Intasome: A Prototype View of the Target of Integrase Inhibitors

Viruses, 2010
The HIV-1 integrase enzyme is essential for integrating the viral DNA into the host chromosome. Infection is aborted in the absence of integration, making integrase an attractive antiviral target. Recently approved inhibitors of integrase bind tightly to
Robert Craigie, Zhiqi Yin
doaj   +1 more source

Detection of HIV-1 infection in dried blood spots from a 12-year-old ABO bedside test card [PDF]

, 1998
Background and Objectives: We tested dried blood from an ABO bedside test card which had been stored at room temperature for 12 years, to prove that a patient with HIV-1 infection had been infected by blood transfusion. Materials and Methods: Immunoblots
Eberle, J., Emminger, Ch., Gürtler, L., Mayer, G., Strobel, Erwin   +4 more
core   +1 more source

Comparative biochemical analysis of HIV-1 subtype B and C integrase enzymes

Retrovirology, 2009
Background Integrase inhibitors are currently being incorporated into highly active antiretroviral therapy (HAART). Due to high HIV variability, integrase inhibitor efficacy must be evaluated against a range of integrase enzymes from different subtypes ...
Kuhl Björn D, Donahue Daniel A, Faltenbacher Verena H, Sloan Richard D, Bar-Magen Tamara, Oliveira Maureen, Xu Hongtao, Wainberg Mark A   +7 more
doaj   +1 more source

Adaptive HIV-1 evolutionary trajectories are constrained by protein stability [PDF]

, 2017
Despite the use of combination antiretroviral drugs for the treatment of HIV-1 infection, the emergence of drug resistance remains a problem. Resistance may be conferred either by a single mutation or a concerted set of mutations.
Kandathil, Shaun M., Lovell, Simon C., Olabode, Abayomi S., Robertson, David L.   +3 more
core   +2 more sources

HIV-1 integrase modulates the interaction of the HIV-1 cellular cofactor LEDGF/p75 with chromatin

Retrovirology, 2011
Background Chromatin binding plays a central role in the molecular mechanism of LEDGF/p75 in HIV-1 DNA integration. Conflicting results have been reported in regards to the relevance of the LEDGF/p75 chromatin binding element PWWP domain in its HIV-1 ...
Garcia-Rivera Jose A, Kugelman Jeffrey R, Morales Elisa, Bueno Murilo TD, Astiazaran Paulina, Llano Manuel   +5 more
doaj   +1 more source

Dolutegravir interactions with HIV-1 integrase-DNA: structural rationale for drug resistance and dissociation kinetics. [PDF]

PLoS ONE, 2013
Signature HIV-1 integrase mutations associated with clinical raltegravir resistance involve 1 of 3 primary genetic pathways, Y143C/R, Q148H/K/R and N155H, the latter 2 of which confer cross-resistance to elvitegravir. In accord with clinical findings, in
Felix DeAnda, Kendra E Hightower, Robert T Nolte, Kazunari Hattori, Tomokazu Yoshinaga, Takashi Kawasuji, Mark R Underwood   +6 more
doaj   +1 more source

Clinical use of HIV integrase inhibitors : a systematic review and meta-analysis [PDF]

, 2013
Background: Optimal regimen choice of antiretroviral therapy is essential to achieve long-term clinical success. Integrase inhibitors have swiftly been adopted as part of current antiretroviral regimens.
A Talbot, AJ Viera, Annemarie M. J. Wensing, AR Zolopa, Axel Fun, B Grinsztejn, B Taiwo, B Young, C Cohen, C Garrido, D McMahon, D Moher, DK Owens, DV Cordery, E DeJesus, E Martinez, E Vispo, EM Gardner, F Caby, F Canducci, F Smith, H Byakwaga, H Hatano, J Reynes, J van Lunzen, JJ Eron, JJ Eron Jr, JK Rockstroh, JL Lennox, JL Lennox, JM Gatell, JM Molina, JR Santos, L Van Wesenbeeck, L Wittkop, Linos Vandekerckhove, Luis Menéndez-Arias, M Harris, M Markowitz, M Markowitz, MA Thompson, MJ Buzon, MJ Kozal, Monique Nijhuis, N Mantel, Nele Brusselaers, O Goethals, PE Sax, Peter Messiaen, R Qaqish, R Relevo, RT Gandhi, RT Gandhi, RT Steigbigel, RT Steigbigel, S Gallien, S Nozza, V Dahl, W Towner, Y Yazdanpanah   +59 more
core   +8 more sources

Switching from a protease inhibitor-based regimen to a dolutegravir-based regimen : a randomized clinical trial to determine the effect on peripheral blood and ileum biopsies from antiretroviral therapy-suppressed human immunodeficiency virus-infected individuals [PDF]

, 2018
Background: Optimization of combination antiretroviral therapy (cART) can impact the human immunodeficiency virus (HIV) reservoir. We evaluated the effect on the HIV reservoir in peripheral blood and ileum biopsies in patients switching from boosted ...
Blanco, Julià, Crespo, Manel, De Clercq, Laura, Gálvez, Cristina, Jimenez, Montse, Martinez-Picado, Javier, Moron-Lopez, Sara, Navarro, Jordi, Puertas, Maria C, Ribas, Bibiana Planas, Rutsaert, Sofie, Salgado, Maria, Torrella, Ariadna, Universitat Autònoma de Barcelona, Urrea, Víctor, Vandekerckhove, Linos   +15 more
core   +3 more sources